Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
Science Translational Medicine | March 3, 2021 | Volume: 13 | Issue: 583 | Pages: No page available
10.1126/scitranslmed.abc8980
| PMID 33658358
Teplizumab treatment of nondiabetic relatives at high risk for T1D induces partially exhausted CD8 + T cells and improves beta cell function.